3660/10 | Tocris Bioscience 3660/10 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Tocris Bioscience

product type :

chemical

product name :

3660/10

catalog :

3660/10

quantity :

10 mg (also 50 mg)

price :

334 USD

citations: 9

Reference
Johnson J, De Veaux N, Rives A, Lahaye X, Lucas S, Perot B, et al. A Comprehensive Map of the Monocyte-Derived Dendritic Cell Transcriptional Network Engaged upon Innate Sensing of HIV. Cell Rep. 2020;30:914-931.e9 pubmed publisher
Catanese A, Olde Heuvel F, Mulaw M, Demestre M, Higelin J, Barbi G, et al. Retinoic acid worsens ATG10-dependent autophagy impairment in TBK1-mutant hiPSC-derived motoneurons through SQSTM1/p62 accumulation. Autophagy. 2019;:1-19 pubmed publisher
Metzler M, Raja S, Elliott K, Friedl R, Tran N, Brugmann S, et al. RDH10-mediated retinol metabolism and RARα-mediated retinoic acid signaling are required for submandibular salivary gland initiation. Development. 2018;145: pubmed publisher
Ho V, Hofs E, Elisia I, Lam V, Hsu B, Lai J, et al. All Trans Retinoic Acid, Transforming Growth Factor ? and Prostaglandin E2 in Mouse Plasma Synergize with Basophil-Secreted Interleukin-4 to M2 Polarize Murine Macrophages. PLoS ONE. 2016;11:e0168072 pubmed publisher
Flamini M, Gauna G, Sottile M, Nadin B, Sanchez A, Vargas Roig L. Retinoic acid reduces migration of human breast cancer cells: role of retinoic acid receptor beta. J Cell Mol Med. 2014;18:1113-23 pubmed publisher
Johansson H, Sanchez B, Mundt F, Forshed J, Kovács A, Panizza E, et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun. 2013;4:2175 pubmed publisher
Martin J, Beriou G, Heslan M, Chauvin C, Utriainen L, Aumeunier A, et al. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid. Mucosal Immunol. 2014;7:101-13 pubmed publisher
Liang D, Zuo A, Shao H, Born W, O Brien R, Kaplan H, et al. Retinoic acid inhibits CD25+ dendritic cell expansion and ?? T-cell activation in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2013;54:3493-503 pubmed publisher
Chen X, Dodge J, Komorowski R, Drobyski W. A critical role for the retinoic acid signaling pathway in the pathophysiology of gastrointestinal graft-versus-host disease. Blood. 2013;121:3970-80 pubmed publisher

product information

master code :

3660

SKU :

3660/10

product name :

BMS 195614

unit size :

10 mg (also 50 mg)

description :

Selective RAR antagonist

target :

Retinoic Acid Receptor Antagonists

category :

Small Molecules

purity :

98%

observed molecular weight :

448.51

url print :

?utm_source=labome&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

details of functionality :

BMS 195614 is a neutral retinoic acid receptor (RAR) -selective antagonist (Ki = 2.5 nM). Displays no significant effect on nuclear receptor corepressor (NCoR) binding; moderately decreases SMRT binding to RAR. Antagonizes agonist-induced coactivator (CoA) recruitment.

top caption :

Selective RAR antagonist

extended description :

Selective RAR antagonist

chemical name text :

4-[[[5,6-Dihydro-5,5-dimethyl-8-(3-quinolinyl)-2-naphthalenyl]carbonyl]amino]benzoic acid

formula :

C29H24N2O3

formula text :

C29H24N2O3

cas num :

182135-66-6

USD :

334 USD

product details :

Selective RAR antagonist

alt names :

BMS614

storage :

Store at -20░C